HIIFS
TGTX icon

Harel Insurance Investments & Financial Services’s TG Therapeutics TGTX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-820
Closed -$30K – 502
2025
Q2 		$30K Hold
820
– – ﹤0.01% 375
2025
Q1 		$32K Hold
820
– – ﹤0.01% 394
2024
Q4 		$25K Hold
820
– – ﹤0.01% 371
2024
Q3 		$19K Hold
820
– – ﹤0.01% 422
2024
Q2 		$15K Buy
+820
New +$13.1K ﹤0.01% 459

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Harel Insurance Investments & Financial Services's TGTX Position: Q3 2025 in Review

Harel Insurance Investments & Financial Services sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 820 shares — an estimated $30K sold.

Harel Insurance Investments & Financial Services first reported a position in TGTX in Q2 2024 and held it in 5 quarters. The position peaked at $32K in Q1 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Harel Insurance Investments & Financial Services reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 820 TG Therapeutics shares in Q3 2025, an estimated $30K.
  • Harel Insurance Investments & Financial Services first reported a position in TG Therapeutics in Q2 2024 and held it in 5 quarters.
  • Harel Insurance Investments & Financial Services's TG Therapeutics position peaked at $32K in Q1 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q3 2025, filed 29 Oct 2025.